CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

The Hospital Readmissions Reduction Program Nationwide Perspectives and Recommendations: A JACC: Heart Failure Position Paper Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE Percutaneous Atriotomy for Levoatrial–to–Coronary Sinus Shunting in Symptomatic Heart Failure: First-in-Human Experience Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors Guideline‐Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient‐Pooled Analysis From the KorHF and KorAHF Registries Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction"

Original ResearchVolume 3, Issue 5, October 2018

JOURNAL:JACC: Basic to Translational Science Article Link

Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors

S Verma, S Rawat, KL Ho et al. Keywords: cardiac efficiency; db/db; glucose oxidation; ketone oxidation; sodium-glucose co-transporter-2 inhibitors

FULL TEXT PDF